Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Core Viewpoint - Savara Inc. is facing a securities fraud class action lawsuit due to misleading statements regarding its Biologics License Application for MOLBREEVI, which led to significant stock price decline and investor losses [1][4][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Savara securities between March 7, 2024, and May 23, 2025, with a deadline of November 7, 2025, to participate as a lead plaintiff [1][5]. - The lawsuit alleges that Savara made materially false and misleading statements about its business and operations, particularly regarding the completeness of the MOLBREEVI BLA submission to the FDA [4][5]. - The FDA issued a refusal-to-file letter for the MOLBREEVI BLA on May 27, 2025, citing insufficient information, which led to a 31.7% drop in Savara's stock price, closing at $1.94 per share [2][3]. Group 2: Financial Impact - Following the FDA's refusal-to-file letter, Guggenheim lowered its price target for Savara, indicating potential delays in commercialization and the likelihood of additional capital raises [2][4]. - The lawsuit claims that the delay in regulatory approval for MOLBREEVI increased the likelihood of Savara needing to raise additional capital, further impacting investor confidence [4].